October 19th 2023
According to Stuart, the agreement will grant Glaukos exclusive worldwide rights to develop and commercialize the company’s ST-113 drug candidate for neuroprotection in glaucoma.
July 8th 2023
The company announced its contract manufacture, NextPharma, completed filling of the drug materials into strips of 10 single-use vials for use in upcoming glaucoma trial.
June 5th 2023
The ophthalmic solution from VivaVision is being studied for the treatment of glaucoma.
May 31st 2023
Therapeutic has fewer adverse effects in patients with POAG, OHT.
May 16th 2023
According to the company, its new 20,000-square-foot facility in Hayward, California, includes cGMP suites, developmental and testing laboratories, equipped with single use bioreactors.
Trinity geneticists develop novel gene therapy for glaucoma
Researchers at the Smurfit Institute of Genetics, in collaboration with the biotechnology company Exhaura Ltd., have shown that a gene therapy-based approach can decrease intraocular pressure in pre-clinical models of glaucoma.
Alembic pharmaceuticals announces USFDA Final Approval for brimonidine tartrate ophthalmic solution 0.15%.
Brimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma.
Skye Bioscience receives positive safety review of topical cannabinoid receptor type 1 agonist after second cohort of phase 1 study
SBI-100 Ophthalmic Emulsion is a synthetic cannabinoid derivative to treat glaucoma and ocular hypertension.
Glaucoma 360: Drug targets and reduces episcleral venous pressure in glaucoma
Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, took the podium at the New Horizons Forum at the Glaucoma 360 conference in San Francisco to discuss the performance of the company’s episcleral venous pressure eyedrop, QLS-111.
Study: Atropine drops after glaucoma surgery may impair vision, prolong rehabilitation
Based on their findings, an international team of researchers is discouraging the application of atropine as a standard therapy for trabeculectomy surgery.
Nicox outlines future development, partnership plans for NX 470 in glaucoma
The company said it plans to generate clinical data aiming to demonstrate the potential retinal benefits of NCX 470 in order to add significant therapeutic value to the product profile in glaucoma.
NIH backing first-in-class engineered mechanosensitive channel based gene therapy for glaucoma
Nanoscope Technologies LLC announced this week it has received Direct Phase II SBIR grant from National Institutes of Health for developing an innovative approach to autonomously regulate pressure for treatment of Glaucoma in a gene-agnostic manner.
The need for precision management in glaucoma moves field forward
Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and adverse effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.
Study focuses on technology to unveil optical texture and trajectories of the axonal fiber bundles on retina
A research team led by the Department of Ophthalmology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong, with collaborators from the Faculty of Medicine of The Chinese University of Hong Kong and local and international partners, have developed a new technology ROTA to unveil the optical texture and trajectories of the axonal fiber bundles on the retina.
Study: Age at time of Type 2 diabetes or hypertension diagnosis linked to glaucoma
Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.
Alternative delivery of glaucoma medications more than a dream
Bausch + Lomb, Sanoculis announce strategic agreements to address unmet needs in glaucoma
Bausch + Lomb has made an equity investment in Sanoculis and has entered into an exclusive European distribution agreement for MIMS minimally invasive surgical procedure.
Selecting the right topical glaucoma therapy is important
Janet B. Serle, MD, discusses the pros and cons of various treatment options.
Nicox’s NCX 470 Dolomites Phase 2 results published in Journal of Glaucoma
NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once daily dosed NCX 470
Travoprost intracameral implant shows efficacy in topical form
Device demonstrates potential as a durable, sustained-release glaucoma therapy
iSTAR Medical continues market expansion with first MINIject® surgeries in the UK
The company announced the expansion of its commercial rollout of its MIGS implant to the UK
Graybug Vision announces pipeline expansion
The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.
Glaucoma Research Foundation honored Vanderbilt’s David Calkins, PhD, with 2022 President’s Award at annual gala
Vanderbilt’s David Calkins, PhD, was honored with the 2022 President’s Award, presented by the Glaucoma Research Foundation, at the Glaucoma 360 Annual Gala last month.
Eliminating nonadherence: Leaving the glaucoma drops in the dust
The glaucoma toolbox is expanding to include laser, drug delivery systems, and minimally invasive glaucoma surgery.
Micro-bypass stent implant during cataract surgery: lower IOP, fewer medications
Mark Gallardo, MD, reports 12-month outcomes of iStent inject® combined with cataract surgery in a predominantly Hispanic patient population with mild to moderate open-angle glaucoma (OAG) and comorbid cataract.
Factors to consider in IOP elevations associated with vitreoretinal treatments
Basil Williams, Jr., MD, reports on the association between development of elevated intraocular pressure and numerous commonly performed vitreoretinal treatments.
MIGS helping to personalize glaucoma surgery options
Although minimally invasive procedure gives hope, additional research is required.
The 2 faces of glaucoma
Pressure-dependent optic nerve disease, retinal disease.
Pivotal study data drive glaucoma patient treatment decisions
Two trials examine factors affecting the risk of disease.
Study: Lower IOP, medication burden in OAG patients
MIGS drainage device offers hope for challenging cases.
An eye toward plateau iris and its implications
Exploring subtleties helps ophthalmologists understand postop surprises, drug reactions.
Research: Treatment targets steroid-induced OHT
Measurements from multiple studies show benefits of rho-kinase inhibition.
IPL offers glaucoma biomarker for early-stage disease
Visible-light optical coherence tomography proves valuable in studies.
Unraveling the genetics of glaucoma
Details enhance knowledge of biological pathways that contribute to disease pathogenesis.
Home IOP monitoring may be aftereffect of COVID-19 pandemic
Option could prove to enhance safety for both patients and staff.
2 Clarke Drive Cranbury, NJ 08512